RSM logo
Annals of Clinical Biochemistry

Home Current issue Browse archive Alerts About the journal Feedback
 
Ann Clin Biochem 2008;45:218-220
doi:10.1258/acb.2007.007117
© 2008 Association for Clinical Biochemistry

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vendrame, F.
Right arrow Articles by Morano, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Case Report

Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis

Francesco Vendrame 1 2, Antonella Verrienti 2, Claudio Parlapiano 2, Sebastiano Filetti 2, Francesco Dotta 3  and Susanna Morano 2


1 Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; 2 Department of Clinical Sciences, University ‘La Sapienza’, 00161 Rome, Italy; 3 Diabetes Unit, Department of Internal Medicine, Endocrine and Metabolic Sciences and Biochemistry, University of Siena, 53100 Siena, Italy


Corresponding author: Dr Francesco Dotta, U.O. di Diabetologia, No. 3 Lotto 5S, Policlinico ‘Le Scotte’, Viale Bracci 18, 53100 Siena, Italy. Email: fradotta{at}tin.it


In Western countries, thyrotoxic periodic paralysis (TPP) is a rare condition with only sporadic cases described so far. Here, we describe a 29-year-old Italian man who presented with leg weakness and hypokalaemia. Treatment with intravenous potassium resulted in a rapid resolution of symptoms. TPP as the underlying cause was suggested by suppressed thyroid-stimulating hormone (TSH), elevated free T3 and free T4, and the presence of TSH-receptor antibodies (TRAB). Genetic analysis showed no mutations in the candidate exons of calcium (CACN1AS), potassium (KCNE3) and sodium (SCN4A) channel genes. However, we identified the presence of two single nucleotide polymorphisms (SNPs), 1491C > T and 1551 T > C, in exon 11 of the CACN1AS gene. Although the 1491C > T SNP is not apparently involved in the pathogenesis of the disease, the 1551 T > C SNP has been associated with TPP in Asians and reported in only one case in European Caucasians. Further investigations are needed to clarify whether such polymorphisms have a role in the disease pathogenesis in Caucasians.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




History of the London Clinic